Last reviewed · How we verify

Perampanel Oral Tablet — Competitive Intelligence Brief

Perampanel Oral Tablet (Perampanel Oral Tablet) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: AMPA receptor antagonist. Area: Neurology.

marketed AMPA receptor antagonist AMPA receptor (GluA1-GluA4) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Perampanel Oral Tablet (Perampanel Oral Tablet) — University of Arizona. Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Perampanel Oral Tablet TARGET Perampanel Oral Tablet University of Arizona marketed AMPA receptor antagonist AMPA receptor (GluA1-GluA4)
E2007 (perampanel) E2007 (perampanel) Eisai Inc. phase 3 AMPA receptor antagonist AMPA receptor (GluA1-GluA4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (AMPA receptor antagonist class)

  1. Eisai Inc. · 1 drug in this class
  2. University of Arizona · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Perampanel Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/perampanel-oral-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: